XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net income (loss) including non-controlling interests $ 468,314 $ (35,265)
Adjustments to reconcile net income (loss) including non-controlling interests to net cash provided by operating activities:    
Depreciation, depletion and amortization 44,673 39,990
Gain on sale of properties (520,421) (88)
Impairment 0 3
Deferred income taxes (7) (3,654)
Derivative instruments 367,922 181,515
Income from investment in unconsolidated affiliate (60,137) 0
Equity-based compensation expenses 4,848 2,198
Deferred financing costs amortization and other 3,433 2,320
Working capital and other changes:    
Change in accounts receivable, net (111,813) (60,542)
Change in inventory 667 4,506
Change in prepaid expenses (369) 1,089
Change in accounts payable, interest payable and accrued liabilities 52,122 62,195
Change in other assets and liabilities, net 16,348 (3,854)
Net cash provided by operating activities 265,580 190,413
Cash flows from investing activities:    
Capital expenditures (48,831) (21,958)
Proceeds from divestitures, net of OMP cash 147,056 2,686
Costs related to divestitures (11,368) 0
Derivative settlements (70,670) (22,596)
Distributions from investment in unconsolidated affiliate 13,116 0
Net cash provided by (used in) investing activities 29,303 (41,868)
Cash flows from financing activities:    
Proceeds from revolving credit facilities 15,000 159,500
Principal payments on revolving credit facilities 0 (635,500)
Proceeds from issuance of senior unsecured notes 0 450,000
Deferred financing costs (9) (11,737)
Common control transaction costs 0 (4,111)
Purchases of treasury stock (4,132) 0
Dividends paid (70,579) (7,535)
Distributions to non-controlling interests 0 (6,029)
Payments on finance lease liabilities (229) (311)
Proceeds from warrants exercised 457 0
Other 0 6
Net cash used in financing activities (59,492) (55,717)
Increase in cash and cash equivalents 235,391 92,828
Cash and cash equivalents:    
Beginning of period 174,783 20,226
End of period 410,174 113,054
Supplemental non-cash transactions:    
Change in accrued capital expenditures 17,504 6,909
Change in asset retirement obligations (428) 1,035
Investment in unconsolidated affiliate 568,312 0
Note receivable from divestiture $ 0 $ 2,900